MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)

被引：0
|
作者：
Burchardt, A. [1 ]
Andorsky, D. J. [2 ]
Schmidt, B. [3 ]
La Rosee, P. [4 ]
Graeven, U. [5 ]
Czuczman, M. [6 ]
Llorente, M. [6 ]
Li, J. [6 ]
Sharman, J. [7 ]
机构：
[1] Justus Liebig Univ Giessen, Giessen, Germany
[2] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA
[3] Hamatoonkol Uberortliche Gemeinschaftspraxis Pasi, Munich, Germany
[4] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany
[5] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol & Gastroenterol, Monchengladbach, Germany
[6] Celgene Corp, Summit, NJ USA
[7] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V608
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [31] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [32] Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma
    Moosmann, Peter
    Heizmann, Marc
    Kotrubczik, Nina
    Wernli, Martin
    Bargetzi, Mario
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 149 - 152
  • [33] A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
    Chen, Robert
    Frankel, Paul
    Popplewell, Leslie
    Siddiqi, Tanya
    Ruel, Nora
    Rotter, Arnold
    Thomas, Sandra H.
    Mott, Michelle
    Nathwani, Nitya
    Htut, Myo
    Nademanee, Auayporn
    Forman, Stephen J.
    Kirschbaum, Mark
    HAEMATOLOGICA, 2015, 100 (03) : 357 - 362
  • [34] LENALIDOMIDE PLUS RITUXIMAB LEADS TO A HIGH RATE OF DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA
    Dutia, M.
    Deroock, I.
    Reed-Pease, C.
    Tuscano, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 186 - 186
  • [35] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    ANNALS OF ONCOLOGY, 2006, 17 : 200 - 200
  • [36] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
  • [37] MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.
    Andorsky, David Jacob
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn
    Lansigan, Frederick
    Reynolds, Chris
    Foon, Kenneth A.
    Li, Jiahui
    Llorente, Mary
    Rummel, Mathias J.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Andreadis, Charalambos
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (01): : XVIII - XIX
  • [39] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
    Burke, J. M.
    Andorsky, D. J.
    Yacoub, A.
    Melear, J.
    Coleman, M.
    Kolibaba, K.
    Brooks, H.
    Bitran, J.
    Fanning, S.
    Lansigan, F.
    Ricker, J. L.
    Foon, K.
    Llorente, M.
    Li, J.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 249 - 250
  • [40] Subgroup analyses of patients aged ≥70 years in AUGMENT: Phase III randomized study of Lenalidomide plus rituximab (R2) vs rituximab plus placebo (R-placebo) in patients with Relapsed/Refractory (R/R) indolent Non-Hodgkin Lymphoma (iNHL)
    La Rosee, P.
    Graeven, U.
    Leonard, J. P.
    Gribben, J.
    Zhang, H.
    Nowakowski, G.
    Izutsu, K.
    Fowler, N. H.
    Thieblemont, C.
    Zinzani, P. L.
    Kalambakas, S.
    Fustier, P.
    Wu, C.
    Trneny, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 68 - 68
12345